title: The influence of intraarterial high-dose cisplatin with concomitant irradiation on arterial microanastomosis: an experimental study.
abstract: OBJECTIVE
  In this experimental study with rabbits, the influence of intraarterial high-dose cisplatin with concomitant irradiation on arterial microanastomoses was evaluated to determine their impact on free-tissue transfers.
  
  
  METHODS
  The right and left iliac arteries of 10 rabbits were injected with 150 mg/m of cisplatin (group 1). To serve as physiological controls, the iliac arteries of 10 other rabbits were injected with the same volume of saline (group 2). Hypofractionated radiotherapy was given to the right inguinal area of all rabbits using a Co unit, 1.25 MeV, and an SSD of 80 cm for 25 Gy at 5 fractions a day for 5 days (groups 1A and 2A) and the left inguinal areas remained unirradiated (groups 1B and 2B). Both femoral arteries of all 20 rabbits were transected and anastomosed using microsurgical techniques on day 7 after the treatment. All femoral artery anastomoses were examined under anesthesia for pulsatile blood flow 14 days after the surgery. Arteries, including the anastomotic site, were harvested and fixed for histologic evaluation by light microscopy and transmission electron microscopy.
  
  
  RESULTS
  Microscopic evaluation showed that all femoral artery anastomoses had good, pulsatile blood flow. Histologic examination of the femoral artery anastomotic site revealed changes of the arterial walls that varied between the groups. Evidence of intimal changes included detachment of endothelial cells in the intimal layer, edema of the endothelial cells in the intima, intimal thickening, separation of the intima from the tunica media, and collagen deposition. Evidence of damage to the tunica media included vacuolation and disarray of the smooth muscle cells, fibrinoid necrosis, and hemorrhage. The damage was most pronounced in the arteries that received both intraarterial cisplatin and radiotherapy (group 1A). The degree of damage diminished in the arteries of the radiotherapy-alone group (group 2A) and the intraarterial cisplatin-alone arteries (group 1B) compared with the control arteries (group 2B). Despite the arterial damage after irradiation and/or cisplatin, the patency rates after vascular anastomosis were 100% for every group.
  
  
  CONCLUSIONS
  Although damage to the arterial walls in the group that received intraarterial high-dose cisplatin with concomitant irradiation was most obvious, there were no differences in the patency rates after vascular anastomosis between any of the groups. Thus, after intraarterial high-dose cisplatin with concomitant irradiation, the femoral arteries can be used with caution as recipient vessels for free-tissue transfer.
authors.affiliation: Division of Radiation Oncology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
authors.forename: Zhong-He
authors.initials: ZH
authors.lastname: Wang
authors.forename: Shi-Zhou
authors.initials: SZ
authors.lastname: Zhang
authors.forename: Zhi-Yuan
authors.initials: ZY
authors.lastname: Zhang
authors.forename: Chen-Ping
authors.initials: CP
authors.lastname: Zhang
authors.forename: Hai-Sheng
authors.initials: HS
authors.lastname: Hu
authors.forename: Jessica
authors.initials: J
authors.lastname: Kirwan
authors.forename: William M
authors.initials: WM
authors.lastname: Mendenhall
mesh_terms: D000714:Anastomosis, Surgical; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005260:Female; D005263:Femoral Artery / Q000502:physiology; D007083:Iliac Artery / Q000187:drug effects* / Q000528:radiation effects* / Q000601:surgery; D007261:Infusions, Intra-Arterial; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011817:Rabbits; D015996:Survival Rate; D014654:Vascular Patency / Q000187:drug effects; D014656:Vascular Surgical Procedures
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin